The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Sertraline for Prevention of Depression Recurrence in Diabetes Mellitus: A Randomized, Double-blind, Placebo-Controlled Trial
Abstract
CONTEXT: In patients with diabetes mellitus, depression is a prevalent and recurrent problem that adversely affects the medical prognosis. OBJECTIVE: To determine whether maintenance therapy with sertraline hydrochloride prevents recurrence of major depression in patients with diabetes. DESIGN: A randomized, double-blind, placebo-controlled, maintenance treatment trial. Patients who recovered from depression during open-label sertraline treatment continued to receive sertraline (n = 79) or placebo (n = 73) and were followed up for up to 52 weeks or until depression recurred. SETTING: Outpatient clinics at Washington University, St Louis, MO, the University of Washington, Seattle, and the University of Arizona, Tucson. PATIENTS: One hundred fifty-two patients with diabetes (mean age, 52.8 years; 59.9% female; 82.9% with type 2 diabetes) who recovered from major depression (43.3% of those initially assigned) during 16 weeks of open-label treatment with sertraline (mean dose, 117.9 mg/d). INTERVENTION: Sertraline continued at recovery dose or identical-appearing placebo. MAIN OUTCOME MEASURES: The primary outcome was length of time (measured as the number of days after randomization) to recurrence of major depression as defined in DSM-IV. The secondary outcome was glycemic control, which was assessed via serial determinations of glycosylated hemoglobin levels. RESULTS: Sertraline conferred significantly greater prophylaxis against depression recurrence than did placebo (hazard ratio = 0.51; 95% confidence interval, 0.31-0.85; P = .02). Elapsed time before major depression recurred in one third of the patients increased from 57 days in patients who received placebo to 226 days in patients treated with sertraline. Glycosylated hemoglobin levels decreased during the open treatment phase (mean +/- SD glycosylated hemoglobin level reduction, -0.4% +/- 1.4%; P = .002). Glycosylated hemoglobin levels remained significantly lower than baseline during depression-free maintenance (P = .002) and did not differ between treatment groups (P = .90). CONCLUSIONS: In patients with diabetes, maintenance therapy with sertraline prolongs the depression-free interval following recovery from major depression. Depression recovery with sertraline as well as sustained remission with or without treatment are associated with improvements in glycosylated hemoglobin levels for at least 1 year.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988) · Clinical Psychology Review · doi:10.1016/0272-7358(88)90050-5 · Cited by 11,696
The Prevalence of Comorbid Depression in Adults With Diabetes
Anderson, R. J., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.1069 · Cited by 3,926 · cited 1×
“C LINICAL DEPRESSION IS present in 1 of every 4 patients with type 1 or type 2 diabetes mellitus.(1) The psychiatric illness lessens quality of life, diminishing the capacity for pleasure and ability to function.”
BackgroundSelf-citationPrevalence and Treatment of Mental Disorders, 1990 to 2003
Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa043266 · Cited by 1,910
Untreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
Recurrence after recovery from major depressive disorder during 15 years of observational follow-up
Mueller, T. I., Leon, A. C., Keller, M. B., Solomon, D. A., Endicott, J., Coryell, W., Warshaw, M., & Maser, J. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1000 · Cited by 897 · cited 1×
“Once considered primarily benign and curable with treatment, depression now is understood as debilitating, recurring, and in some instances, refractory.(45,48) There is growing awareness of the importance of depression as a risk factor for medical illness,(49) particularly in patients with diabetes or a diabetic predi…”
BackgroundPrevention of Relapse following cognitive therapy vs medications in moderate to severe depression.
Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Young, P. R., Haman, K. L., Freeman, B. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.417 · Cited by 735
Wang, P. S., Berglund, P., & Kessler, R. C. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.9908044.x · Cited by 686
The Association of Comorbid Depression With Mortality in Patients With Type 2 Diabetes
Katon, W. J., Rutter, C., Simon, G., Lin, E. H. B., Ludman, E., Ciechanowski, P., Kinder, L., Young, B., & Von Korff, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2668 · Cited by 640 · cited 1×
“For example, depression increases the risk of developing type 2 diabetes,(51,52) accelerates the presentation of coronary heart disease in both type 1 and type 2 diabetes,(3) and significantly increases the risk of diabetes-related mortality.(6,53,54) Time Table 2.”
BackgroundSelf-citationGoldstein, D. E., Little, R. R., Lorenz, R. A., Malone, J. I., Nathan, D., Peterson, C. M., & Sacks, D. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1761 · Cited by 625 · cited 1×
“The HbA1c level measurement is an aggregate measure of glycemic control over the 120-day period before testing.(34,35) Because of the time interval incorporated in a single HbA1c measurement and the short interval between depression assessments, all of the values obtained following randomization were considered reflec…”
MethodDepression, mortality, and medical morbidity in patients with coronary heart disease
Carney, R. M., & Freedland, K. E. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00111-2 · Cited by 378
Self-citationDepressive Symptoms and Mortality among Persons with and without Diabetes
Zhang, X. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi089 · Cited by 346 · cited 2×
“For example, depression increases the risk of developing type 2 diabetes,(51,52) accelerates the presentation of coronary heart disease in both type 1 and type 2 diabetes,(3) and significantly increases the risk of diabetes-related mortality.(6,53,54) Time Table 2.”
BackgroundRelapse of depression in primary care: Rate and clinical predictors
Lin, E. H. B. (1998) · Archives of Family Medicine · doi:10.1001/archfami.7.5.443 · Cited by 152
Remission onset and relapse in depression
O’Leary, D., Costello, F., Gormley, N., & Webb, M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00086-5 · Cited by 87
Wilson, K. C. M., Mottram, P. G., Ashworth, L., & Abou-Saleh, M. T. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.492 · Cited by 74
Terra, J. L., & Montgomery, S. A. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199803000-00001 · Cited by 51
Cited by
Anxiety disorders and comorbid medical illness
Roy-Byrne, P. P., Davidson, K. W., Kessler, R. C., Asmundson, G. J. G., Goodwin, R. D., Kubzansky, L., Lydiard, R. B., Massie, M. J., Katon, W., Laden, S. K., et al. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.12.006 · Cited by 668
The link between depression and diabetes: the search for shared mechanisms
Moulton, C. D., Pickup, J. C., & Ismail, K. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00134-5 · Cited by 670
The Comorbidity of Diabetes Mellitus and Depression
Katon, W. J. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.008 · Cited by 307
A Review of Treating Depression in Diabetes: Emerging Findings
Markowitz, S. M., Gonzalez, J. S., Wilkinson, J. L., & Safren, S. A. (2011) · Psychosomatics · doi:10.1016/j.psym.2010.11.007 · Cited by 230
Healthy Coping, Negative Emotions, and Diabetes Management
Fisher, E. B., Thorpe, C. T., McEvoy DeVellis, B., & DeVellis, R. F. (2007) · The Diabetes Educator · doi:10.1177/0145721707309808 · Cited by 223
“Do Healthy Coping Interventions Improve Metabolic Control? Well-controlled studies (randomized trials or other adequate control procedures such as multiple baseline) indicate that improved metabolic control results from cognitive-behavioral interventions for depression,(124) stress management intervention,(125) coping…”
Background
Metadata
- Authors
- Lustman, P. J., Clouse, R. E., Nix, B. D., Freedland, K. E., Rubin, E. H., McGill, J. B., Williams, M. M., Gelenberg, A. J., Ciechanowski, P. S., & Hirsch, I. B.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2006-05-01
- Volume
- 63
- Issue
- 5
- Pages
- 521
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2012704942
- Cited by
- 202
- References
- 16
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.